Allergan PLC. (NYSE:AGN) Shares Sold by Nuveen Asset Management LLC
Nuveen Asset Management LLC cut its position in Allergan PLC. (NYSE:AGN) by 49.0% during the first quarter, Holdings Channel reports. The fund owned 31,762 shares of the company’s stock after selling 30,466 shares during the period. Nuveen Asset Management LLC’s holdings in Allergan PLC. were worth $7,589,000 as of its most recent filing with the SEC.
Other large investors have also modified their holdings of the company. Cpcm LLC increased its stake in shares of Allergan PLC. by 30.9% in the first quarter. Cpcm LLC now owns 1,443 shares of the company’s stock worth $345,000 after buying an additional 341 shares during the last quarter. Piedmont Investment Advisors LLC increased its stake in shares of Allergan PLC. by 0.7% in the first quarter. Piedmont Investment Advisors LLC now owns 71,044 shares of the company’s stock worth $16,974,000 after buying an additional 504 shares during the last quarter. Ballentine Partners LLC increased its stake in shares of Allergan PLC. by 5.2% in the first quarter. Ballentine Partners LLC now owns 2,875 shares of the company’s stock worth $688,000 after buying an additional 142 shares during the last quarter. Jacobi Capital Management LLC increased its stake in shares of Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock worth $112,000 after buying an additional 22 shares during the last quarter. Finally, Pacific Center for Financial Services increased its stake in shares of Allergan PLC. by 805.1% in the first quarter. Pacific Center for Financial Services now owns 534 shares of the company’s stock worth $128,000 after buying an additional 475 shares during the last quarter. Institutional investors and hedge funds own 84.77% of the company’s stock.
Allergan PLC. (NYSE AGN) traded up 0.29% on Friday, reaching $232.88. The company’s stock had a trading volume of 1,820,899 shares. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80. The company’s 50 day moving average price is $245.93 and its 200-day moving average price is $238.13. The stock has a market cap of $77.85 billion, a PE ratio of 7.10 and a beta of 1.16.
Allergan PLC. (NYSE:AGN) last released its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same period last year, the business posted $3.35 EPS. On average, equities analysts expect that Allergan PLC. will post $16.27 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Friday, August 18th will be paid a $0.70 dividend. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.20%. Allergan PLC.’s dividend payout ratio (DPR) is currently 9.95%.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://theolympiareport.com/2017/08/12/allergan-plc-nyseagn-shares-sold-by-nuveen-asset-management-llc.html.
A number of brokerages have weighed in on AGN. UBS AG reiterated an “outperform” rating and issued a $275.00 target price on shares of Allergan PLC. in a report on Wednesday. Deutsche Bank AG reiterated a “buy” rating and issued a $278.00 target price (up from $273.00) on shares of Allergan PLC. in a report on Wednesday. BidaskClub cut Allergan PLC. from a “buy” rating to a “hold” rating in a research note on Wednesday. Wells Fargo & Company reissued an “outperform” rating and issued a $280.00 price objective (up previously from $270.00) on shares of Allergan PLC. in a research note on Wednesday. Finally, Credit Suisse Group set a $288.00 price objective on Allergan PLC. and gave the company a “buy” rating in a research note on Saturday, August 5th. Eight analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $274.49.
In other news, Director Nesli Basgoz sold 1,889 shares of the firm’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.36% of the company’s stock.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with Analyst Ratings Network's FREE daily email newsletter.